Bifogade filer
PDF
Kurs
-7,20%
Kalender
| Est. tid* | ||
| 2025-11-25 | 05:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-26 | 05:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-23 | - | Årsstämma |
| 2025-05-23 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-02 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-26 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-13 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-26 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-19 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2023-05-17 | - | Årsstämma |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-14 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-27 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-11 | - | Extra Bolagsstämma 2022 |
| 2022-04-08 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2022-04-07 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-21 | - | Årsstämma |
| 2021-04-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-08 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-07 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2020-06-11 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-09 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2019-04-08 | - | Årsstämma |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-07 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-10 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2018-04-09 | - | Årsstämma |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-09 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2017-05-08 | - | Årsstämma |
| 2017-05-05 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-20 | - | Bokslutskommuniké 2016 |
| 2016-11-11 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-10 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2016-05-09 | - | Årsstämma |
| 2016-05-04 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-10-23 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-14 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Double Bond Pharmaceutical's third patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in China. Patent approval provides protection for the treatment method and the design of composition for DBP's front-line product SA-033.
"We are very pleased because it is an important milestone in the development of balanced product pipeline", - comments Igor Lokot, CEO of DBP.
More about SA-033: SA-033 is the first drug candidate that DBP has developed using its innovative drug delivery technology BeloGal®. Due to innovative formulation controls targeting of doxorubicin to the liver, the concentration of the active substance in the desired target organ increases, which enhances efficacy and reduces the toxic side effects that are common in systemic chemotherapy.
More about BeloGal®: BeloGal® is DBP's innovative drug-delivery platform which targets pharmaceutically active compounds to lung or liver. Video presentation: https://youtu.be/2PKi51PW75Q
This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-10-2021 10:57 CET.